Abstract
We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).
Keywords: COVID-19; Monoclonal antibodies; Multiple sclerosis; Treatment.
All Keywords
【저자키워드】 COVID-19, multiple sclerosis, monoclonal antibodies, Treatment., 【초록키워드】 Treatment, COVID-19 vaccine, monoclonal antibody, anti-SARS-CoV-2, symptomatic, disease, change, anti-CD20, Mild-to-moderate, Multiple, FIVE, reported, reduced, treated, absence, 【제목키워드】 antibody, Mild-to-moderate, case sery,
【저자키워드】 COVID-19, multiple sclerosis, monoclonal antibodies, Treatment., 【초록키워드】 Treatment, COVID-19 vaccine, monoclonal antibody, anti-SARS-CoV-2, symptomatic, disease, change, anti-CD20, Mild-to-moderate, Multiple, FIVE, reported, reduced, treated, absence, 【제목키워드】 antibody, Mild-to-moderate, case sery,
{{{ 추상적인 }}}
우리는 경증에서 중등도의 증상을 보이는 COVID-19가 있고 면역고갈성 질환 변형 치료제(항-CD20 단일클론 항체 및 스핑고신-1-인산 조절제)를 사용하고 COVID-19 백신 반응이 감소된 MS 환자 5명에 대해 보고했습니다. 항 SARS-CoV-2 단일 클론 항체로 치료합니다. 특히, 우리는 COVID-19 잔류물 또는 MS 변화(예: 재발 또는 장애)가 없는 경우 MS에서 COVID-19로부터의 회복 속도를 높이기 위해 모노클로날 항체를 사용할 가능성을 보여주었습니다.
{{ 키워드: }} 코로나19; 모노클로날 항체; 다발성 경화증; 치료.